发明授权
- 专利标题： Glucagon antagonists/inverse agonists
- 专利标题（中）： 胰高血糖素拮抗剂/反向激动剂
-
申请号： US10372536申请日： 2003-02-24
-
公开(公告)号： US06953812B2公开(公告)日： 2005-10-11
- 发明人: Anker Steen Jorgensen , Inge Thoger Christensen , Janos Tibor Kodra , Christian Sams , Carsten Behrens , Peter Madsen , Jesper Lau
- 申请人： Anker Steen Jorgensen , Inge Thoger Christensen , Janos Tibor Kodra , Christian Sams , Carsten Behrens , Peter Madsen , Jesper Lau
- 申请人地址： DK Bagsvaerd
- 专利权人： Novo Nordisk, Inc.
- 当前专利权人： Novo Nordisk, Inc.
- 当前专利权人地址： DK Bagsvaerd
- 代理商 Richard W. Bork, Esq.; Reza Green, Esq.; Marc A. Began, Esq.
- 优先权： DK200000984 20000623; DK200001734 20001117
- 主分类号： C07C237/42
- IPC分类号： C07C237/42 ; C07C275/28 ; C07C275/30 ; C07C275/34 ; C07C275/42 ; C07C317/42 ; C07C323/44 ; C07D209/08 ; C07D209/42 ; C07D209/48 ; C07D213/40 ; C07D213/75 ; C07D213/82 ; C07D257/04 ; C07D263/56 ; C07D263/57 ; C07D271/06 ; C07D277/28 ; C07D277/66 ; C07D277/82 ; C07D307/68 ; C07D319/08 ; C07D333/20 ; C07D333/36 ; C07D333/68 ; C07D513/04 ; A01N43/06
摘要：
A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity.
公开/授权文献
- US20040024045A1 Glucagon antagonists/inverse agonists 公开/授权日：2004-02-05
信息查询
